{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:13:26Z","timestamp":1790230406025,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several BCR\u2010ABL1 tyrosine kinase inhibitors (TKIs) are approved for the first\u2010line treatment of chronic phase chronic myeloid leukaemia (CML). Disease control is achieved in the vast majority of patients and disease\u2010specific survival is excellent. Consequently, there is now emphasis on managing comorbidities and minimising treatment\u2010related toxicity. Second\u2010generation TKIs have cardiovascular risks that are greater than with imatinib treatment, but these risks must be balanced against the superior CML responses encountered with more potent TKIs. Cardiovascular risk should be assessed at baseline using a locally validated model based on the Framingham risk equation. Clinicians involved in the care of CML patients should be aware of the vascular complications of TKIs and manage cardiovascular risk factors early to mitigate treatment\u2010related risks. Reversible risk factors, such as dyslipidaemia, smoking, diabetes and hypertension, should be addressed. We summarise the available data on cardiovascular complications in CML patients treated with TKIs. Using the latest evidence and collective expert opinion, we provide practical advice for clinicians to assess, stratify and manage cardiovascular risk in people with CML receiving TKI therapy.<\/jats:p>","DOI":"10.1111\/imj.13716","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T02:05:14Z","timestamp":1517450714000},"page":"5-13","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors"],"prefix":"10.1111","volume":"48","author":[{"given":"David M.","family":"Ross","sequence":"first","affiliation":[{"name":"Department of Haematology Royal Adelaide Hospital and Flinders Medical Centre  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Arthur","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Burbury","sequence":"additional","affiliation":[{"name":"Department of Haematology Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Ko","sequence":"additional","affiliation":[{"name":"MonashHeart, Monash Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K.","family":"Mills","sequence":"additional","affiliation":[{"name":"Division of Cancer Services Princess Alexandra Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[{"name":"Monash Haematology, Department of Haematology Monash Health  Melbourne Victoria Australia"},{"name":"School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Kostner","sequence":"additional","affiliation":[{"name":"Department of Cardiology Mater Hospital and University of Queensland  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"e_1_2_13_2_1","volume-title":"Incidence and Mortality for Chronic Myeloid Leukaemia","author":"Australian Institute of Health and Welfare","year":"2017"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.261"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_2_13_6_1","volume-title":"Guidelines for the Management of Absolute Cardiovascular Disease Risk","author":"National Vascular Disease Prevention Alliance","year":"2012"},{"key":"e_1_2_13_7_1","volume-title":"Cardiovascular Disease: Australian Facts","author":"Australian Institute of Health and Welfare","year":"2011"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00080-2"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1091929"},{"key":"e_1_2_13_13_1","article-title":"Cardiovascular events among patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs)","volume":"128","author":"Sam PY","year":"2016","journal-title":"Blood"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24194"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2306"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1261824"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200503103521023"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/db08-0080"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5580"},{"key":"e_1_2_13_21_1","volume-title":"ICLUSIG (Ponatinib) Product Information","author":"Ariad Pharmaceuticals (Australia) Pty Ltd","year":"2016"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.07.019"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V122.21.257.257","article-title":"Nilotinib exerts direct pro\u2010atherogenic and anti\u2010angiogenic effects on vascular endothelial cells: a potential explanation for drug\u2010induced vasculopathy in CML","volume":"122","author":"Albrecht\u2010Schgoer K","year":"2013","journal-title":"Blood"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2012.09.008"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2015.1049138"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-0125"},{"key":"e_1_2_13_27_1","volume-title":"Coronary Artery Calcium Scoring \u2013 Position Statement","author":"Cardiac Society of Australia and New Zealand","year":"2017"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12410-015-9334-0"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.113.000690"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60784-8"},{"key":"e_1_2_13_31_1","first-page":"CD010680","article-title":"Ankle brachial index for the diagnosis of lower limb peripheral arterial disease","volume":"9","author":"Crawford F","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2014.12.008"},{"key":"e_1_2_13_33_1","first-page":"110","article-title":"Screening of hospitalised diabetic patients for lower limb ischaemia: is it necessary?","volume":"49","author":"Khammash MR","year":"2008","journal-title":"Singapore Med J"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694265"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.104075"},{"key":"e_1_2_13_36_1","volume-title":"General Practice Management of Type 2 Diabetes","author":"The Royal Australian College of General Practitioners","year":"2016"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12496"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.09.003"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-617993"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.13716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.13716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T01:55:21Z","timestamp":1694483721000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.13716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":38,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/imj.13716"],"URL":"https:\/\/doi.org\/10.1111\/imj.13716","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"2018-01-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}